A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension

Home A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension

A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension

Sep 5, 2017 | Posted by ICAMH.org@gmail.com |

Handen B, Anagnostou E, Aman MG, et al. JAACAP. 2017. Available online: DOI: http://dx.doi.org/10.1016/j.jaac.2017.07.790

Low dose antipsychotic medications are often used to manage severe behavioural disturbance in children with Autism Spectrum Disorder (ASD). However, weight gain and metabolic side-effects remain a significant concern to prescribers. This follow-up study shows that metformin (a medicine that helps to control blood sugar levels) can be useful in preventing and maintaining weight loss in these children and that it is generally well-tolerated.

http://www.jaacap.com/article/S0890-8567(17)31180-2/fulltext

Back

A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension

A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension

Find us on